Mirae Asset Healthcare Fund

A Sectoral/Thematic Fund scheme from Mirae Asset Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF769K01ED6).

NAV ₹54.9490 on 16 November 2026.

Expense ratio

Total expense ratio 0.62% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 0.45%, brokerage 0.03%, transaction costs 0.00%, statutory levies including GST 0.14%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year27.0%14.4%-9.1%1.391.49
3 years24.3%14.4%-15.9%1.201.14
5 years17.5%13.9%-18.5%0.760.73

Too little NAV history for the 10-year figures.

Category rank: 4th of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 99.9% of the portfolio.

  1. Sun Pharmaceutical Industries Limited — 10.32%
  2. Divi's Laboratories Limited — 9.97%
  3. Torrent Pharmaceuticals Limited — 6.41%
  4. Laurus Labs Limited — 6.37%
  5. Apollo Hospitals Enterprise Limited — 5.81%
  6. Dr. Reddy's Laboratories Limited — 5.45%
  7. Glenmark Pharmaceuticals Limited — 4.61%
  8. Aurobindo Pharma Limited — 3.73%
  9. Alkem Laboratories Limited — 3.65%
  10. Krishna Institute of Medical Sciences Limited — 3.48%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.